1 / 17

General Principles for Preventing High INR

This guide provides general principles for preventing high INR levels in patients on warfarin therapy. It includes recommendations for dental and dermatological procedures, elective surgery, warfarin dosing, and managing bleeding events. Additionally, it discusses options for warfarin reversal, including the use of prothrombin complex concentrates (PCCs) and vitamin K.

ilset
Download Presentation

General Principles for Preventing High INR

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. General principles for preventing high INR • Simple dental or dermatological procedures may not require interruption to warfarin therapy. • If necessary, warfarin therapy can be withheld 5 days before elective surgery, when the INR usually falls to below 1.5 and surgery can be conducted safely. • General principles for preventing high INR • • Avoid high loading doses of warfarin, • • Potential warfarin–drug interactions need to be considered. • • Aim for an INR level that balances the therapeutic goal with risk factors of bleeding on an individual basis. • • Avoid frequent dose adjustments. • • Avoid excessive increases in dose when INR drifts below target INR range.

  2. Dramatic increase in number of patients receiving OAC • Interindividual variation (environmental and genetic) • Incidence of warfarin associated haemorrhage :fatal haemorrhage 1%/Y. • Reversal :seriousness of bleeding ,balance against thrombotic risk and speed and completeness of reversal • Options include simple dose omission ,vitamin K & factors replacement • FFP is less effective in correction of coagulopathy ,volume overload & slow infusion rate than PCCs • PCCs are also subjected to virus inactivation

  3. PCCs • PCCs are intermediate purity pooled plasma products • only HTDEFIX is licensed in UK for warfarin reversal • PCCs, (‘‘four factor concentrates’’), OR low VII (three) • Amounts of protein C and S • Optimum dose not established. • INR 2–3.9, 25 U/kg; INR 4–5.9, 35 U/kg; INR . 6, 50 U/kg. • Thrombogenicity, exacerbation of DIC are dose related problems, • The current cost in the UK is around 25 pence/unit (total cost for a single treatment for a 70 kg individual £437 -£875. • More expensive than the cost of FFP. ( unit of produced from UK plasma currently costs about £30). • FFP that is methylene blue treated or produced from non-UK plasma is more expensive.)

  4. On the basis of the current evidence, a PCC plus IV vitamin K is the treatment of choice for patients with major haemorrhage. • A dose of 30 U/kg (regardless of INR) • Combination of PCC and FFP covers period before vitamin K1 has reached its full effect. • Vitamin K1 is essential for sustaining the reversal achieved • Pre- and postoperative management of anticoagulation. bridging therapy. • Prolonged immobility ,AF index event requiring anticoagulation occurred more than 3 months prosthetic valves VTE within the preceding 3 months • Unfractionated heparin 24 hours preceding surgery

More Related